Replies to post #114385 on Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

Here read and understand the beginning of why we are now living the Dream!
https://www.prnewswire.com/news-releases/pan-am-cancer-treatment-center-provides-final-hemaxellerate-clinical-data-to-regen-biopharma-inc-for-treatment-of-bone-marrow-suppression-study-598169731.html

Yea RGBP has allowed us to live the dream especially after making enough off those 2 Big Fun 1,000% to 10,000% RGBP Runs to over 8 cent$ Last year to retire early.
RGBP has a Dream team of scientific professionals working for team RGBP and it’s not if but when! LoL!
Past human studies where Successful!
While some claimed they would never happen or the IND’s would not get approved! LoL!
the latest data presented, the patients who apparently benefited after one month maintained their high levels of white blood cells and all 5 patients had increased numbers of white blood cells after 6 months as compared to after 1 month. In addition, all 5 patients had increased numbers of red blood cells and increased numbers of platelets 6 months after treatment as compared to after 1 month.
Now RGBP has much more going for us!
Regen BioPharma Inc's Company Profile
Business Description
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
https://docoh.com/patent/by/companyId/1589150
Preclinical trials

11 Aug 2022 Regen BioPharma has patent protection for NR2F6 Technology
15 Mar 2022 Preclinical trials in Myelodysplastic syndromes in USA (IV) (Regen Biopharma pipeline)
10 Mar 2022 Preclinical development in Breast cancer and Myelodysplastic syndrome is ongoing USA

HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
https://fintel.io/sfs/us/rgbp

[rudyboy]

Let him do, he made already so much money he can´t even tell it anymore.